Biofourmis, a digital therapeutics solution provider endeavoring towards personalized predictive care, announces the completion of its Series C funding round. The $100 million round was led by by SoftBank Vision Fund 2,[1] with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.

The 2015 born company had a busy quarter, involving a lot of business and operational activities, starting from its partnership with ImagineMIC to develop collaborative remote patient monitoring model in January. During the start of the pandemic, the company’s AI-powered remote monitoring platform was launched in Hong Kong to help fight COVID-19. In April, the

company expanded its footprint to Oncology market by acquiring Gaido Health – an AI platform for continuous monitoring of Post-discharge oncology patients. Biofourmis also hired a new CFO, Matt Borowiecki, a month after. In July, it has also launched its AI-powered remote monitoring platform in Singapore, which was followed by the latest funding. The last influx, its Series B funding was closed in May 2019.

In a statement, Kuldeep Singh Rajput, CEO, Biofourmis, says, “COVID-19 is pushing remote monitoring and digital therapeutics to the forefront of medicine. Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy. With this new funding, we will accelerate our global expansion, advance our digital therapeutics pipeline, develop additional care pathways and drive deeper integration with our health system, hospital, pharmaceutical and clinical research clients and partners.”

“We believe predictive health is the future of medicine and Biofourmis is a leader in using AI and machine learning-based solutions to advance digital therapeutics,” says Greg Moon, Managing Partner, SoftBank Investment Advisers. “We are excited to partner with Biofourmis and support their mission of using AI and wearables data to enable personalized care,” adds Greg.

According to Biofourmis, the funding will be leveraged to develop, validate and commercialize several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology and pain, with focus on the United States, and other key markets like Asia.